PIM447 (LGH447)

Catalog No.S7985 Batch:S798501

Print

Technical Data

Formula

C24H23F3N4O.HCl
Molecular Weight 476.92 CAS No. 1210608-43-7(freebase)
Solubility (25°C)* In vitro DMSO 88 mg/mL (184.51 mM)
Ethanol 88 mg/mL (184.51 mM)
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description PIM447 (LGH447) is a novel pan-PIM kinase inhibitor with Ki values of 6 pM, 18 pM, 9 pM for PIM1, PIM2, PIM3 respectively. It also inhibits GSK3β, PKN1, and PKCτ, but at a significantly lower potency with IC50 between 1 and 5 μM (>105-fold differential relative to the Ki on PIMs). PIM447 induces apoptosis.
Targets
Pim1 [1]
(Cell-free assay)		 Pim3 [1]
(Cell-free assay)		 Pim2 [1]
(Cell-free assay)
6 pM(Ki) 9 pM(Ki) 18 pM(Ki)
In vitro The kinase selectivity of PIM447 is first determined in biochemical assays for a panel of 68 diverse protein kinases that included PIM2 as well as 9 lipid kinases. In this panel, only PIM2 is significantly inhibited by PIM447 with an IC50 of <0.003 μM, the lowest sensitivity range for the assay. PIM447 also inhibits GSK3β, PKN1, and PKCτ, but at a significantly lower potency with IC50 between 1 and 5 μM (>105-fold differential relative to the Ki on PIMs). The biochemical IC50 for all other kinases tested in this panel is >9 μM. In follow-up cellular assays of GSK3β inhibition, PIM447 is tested up to 20 μM and is not active[1]. PIM447 is cytotoxic for myeloma cells due to cell-cycle disruption and induction of apoptosis mediated by a decrease in phospho-Bad (Ser112) and c-Myc levels and the inhibition of mTORC1 pathway. PIM447 also inhibits in vitro osteoclast formation and resorption, downregulates key molecules involved in these processes, and partially disrupts the F-actin ring, while increasing osteoblast activity and mineralization[2].
In vivo Low to moderate in vivo CL is observed for PIM447 across species, as CL values of 20, 28, and 8 mL/min/kg are observed in mouse, rat, and dog, respectively. The volume of distribution is consistently large across species, with Vss of 5.3, 6.4, and 3.6 L/kg observed in mouse, rat, and dog, respectively. Additionally, PIM447 exhibits high oral bioavailability across species, as 84%, 70%, and 71% is observed in mouse, rat, and dog, respectively. The stability of PIM447 in human plasma is high, >90% after a 3 h incubation, and the human plasma protein binding of PIM447 is 95%. With the combination of potent in vitro activity and low to moderate CL, PIM447 demonstrates in vivo target modulation (pS6RP), single agent antitumor activity in a KG-1 AML mouse xenograft model, and druglike properties suitable for development[1]. PIM447 significantly reduces the tumor burden and prevents tumor-associated bone loss in a disseminated murine model of human myeloma[2].

Protocol (from reference)

Cell Assay:

[1]
  • Cell lines

    KG-1 cells

  • Concentrations

    0.05, 0.5, and 5 μM

  • Incubation Time

    2 h

  • Method

    Following treatment of KG-1 cells with PIM447 for 2 h at the indicated concentrations, cells are lysed in RIPA buffer. Protein concentration is determined using a BCA assay, and 50 μg of lysate is separated by SDS-PAGE using 10% bis-Tris gels. Proteins are transferred onto 0.2 μm nitrocellulose membrane, and pS6RP/total S6RP are detected. Following incubation with secondary antibodies, antibody binding is detected using ECL Advance.
Animal Study:

[1]
  • Animal Models

    KG-1 AML xenograft mouse model 

  • Dosages

    30 or 100 mg/kg

  • Administration

    oral administration

Customer Product Validation

Data from [Data independently produced by , , Transl Oncol, 2018, 12(2):336-349]

Selleck's PIM447 (LGH447) has been cited by 18 publications

PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer [ Oncogene, 2024, 43(6):406-419] PubMed: 38097734
Nuclear transport surveillance of p53 by nuclear pores in glioblastoma [ Cell Rep, 2023, S2211-1247(23)00893-8] PubMed: 37552992
PIM1 phosphorylates ABI2 to enhance actin dynamics and promote tumor invasion [ J Cell Biol, 2023, 222(6)e202208136] PubMed: 37042842
Defining the Role of PIM in Regulating Cytoskeletal Dynamics and Tumor Cell Invasion in Hypoxia [ The University of Arizona., 2023, ] PubMed: None
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies [ Cancer Res, 2021, canres.1023.2021] PubMed: 34625423
Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies [ Cancer Res, 2021, 81(23):6029-6043] PubMed: 34625423
PIM447 inhibits oncogenesis and potentiates cisplatin effects in hepatoblastoma [ J Pediatr Surg, 2021, S0022-3468(21)00173-1] PubMed: 33762119
2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors [ Chem Pharm Bull (Tokyo), 2021, 69(9):854-861] PubMed: 34470949
Anti-platelet Properties of Pim Kinase Inhibition Is Mediated Through Disruption of Thromboxane A2 Receptor Signalling [ Haematologica, 2020, 28;haematol.2019.223529] PubMed: 32467143
Measurement and models accounting for cell death capture hidden variation in compound response. [ Cell Death Dis, 2020, 20;11(4):255] PubMed: 32312951

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.